Algernon Pharmaceuticals (AGN.C) filed a combined clinical trials of investigational medicinal products and ethics approval application with the United Kingdom Medicines and Healthcare Products Regulatory… Read More »Algernon Pharmaceuticals (AGN.C) files for DMT clinical trials for stroke
Algernon Pharmaceuticals (AGN.C) awarded the contract for the synthesis and manufacture of the psychoactive ingredient and finished product for its AP-188 DMT project to Canadian-based… Read More »Algernon Pharmaceuticals (AGN.C) gets Dalton Pharma Services onboard to synthesize DMT
Algernon Pharmaceuticals (AGN.C) and Charles River Laboratories agreed to have the latter handle Algernon’s DMT pre-clinical studies for their stroke clinical research program today, according… Read More »Algernon Pharmaceuticals (AGN.C) taps Charles River Technologies for DMT pre-clinicals
Algernon Pharmaceuticals (AGN.C) has established a clinical trial program to treat stroke that uses DMT, or (N-dimethyltryptamine) today, according to a press release. The company… Read More »Algernon Pharmaceuticals (AGN.C) to administer microdoses of DMT in newest clinical trial program for stroke patients
Tragedy and trying times brings out both the best and the worst in humanity. We have doctors and nurses risking their health and safety everyday… Read More »Three companies using solid science to fight the COVID-19 virus
